Kim Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Ms. Drapkin currently serves as President and Chief Executive Officer of Graphite Bio, a gene editing company. Previously, Ms. Drapkin was CFO at Jounce Therapeutics since its inception, playing a key role in building Jounce’s financial infrastructure. Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early-stage biotechnology companies. Previously, she was chief financial officer at EPIX Pharmaceuticals and also spent ten years in roles of increasing responsibility within the finance organization at Millennium Pharmaceuticals. Her career began in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Ms. Drapkin served as a member of Yumanity’s board of directors since the completion of the merger of Proteostasis and Yumanity, Inc. and previously served on the board of directors of Proteostasis. She currently serves on the board of directors at Acumen Pharmaceuticals (NASDAQ: ABOS) and Imugene Limited (ASX: IMU), where she chairs the audit committee at both companies.
Ms. Drapkin holds a B.S. in accounting from Babson College.